Innovative Oncology Trial Data Shaping Cancer Care at ESMO 2024
Groundbreaking Innovations in Oncology Trial Data
Across 5 days, the ESMO Congress 2024 will present practice-changing oncology trial data, encouraging early-stage research and innovative approaches to cancer care and management. The meeting will be held both virtually and in-person from September 13-17 in Barcelona, Spain.
Comprehensive Sessions and Presentations
The Congress will encompass 86 late-breaking abstracts presented throughout 3 Presidential Symposiums along with additional Proffered Paper and Mini Oral sessions. The Presidential Symposiums feature two practice-changing trials and one focusing on future perspectives in oncology.
- Phase 3 results of EORTC-GUCG 1333/PEACE-3: Enzalutamide in patients with prostate cancer
- Phase 3 results of POD1UM-303/InterAACT 2: Retifanlimab with carboplatin-paclitaxel for anal cancer
- Phase 3 results from LEAP-012: Transarterial chemoembolization plus lenvatinib and pembrolizumab for liver cancer
- Phase 3 results from EGOT-cx11/GOG-3047: Pembrolizumab plus chemoradiotherapy for cervical cancer
Highlighted Sessions on Patient Care and Technology
Among several vital discussions, a session on oncological counseling will address crucial aspects such as fertility preservation amidst new cancer therapies. Furthermore, presentations will explore antibody-drug conjugates (ADCs) relevant to breast and lung cancers.
Attention will also hone in on young-onset cancers, featuring a special focus on colorectal cancer and discussions around genetic and environmental contributors. Patient advocacy sessions will emphasize the burden of treatment and access issues to oncology medicines.
Advancements Through Technology and AI
Technology’s integration into cancer care will be a key theme with sessions assessing digital innovations and artificial intelligence applications in managing gynecological cancers. Dr. Amy Abernethy will spotlight AI's role in precision oncology, detailing scalable implementations at the congress.
This year's Congress promises to deliver impactful insights and updates in oncology through scientific sessions dedicated to comprehensive discussions on various cancers, policy strategies, and investigative immunotherapies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.